Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (431-440 of 1,126) with videos related to

Pageof 113
Sort By:
European Urology Oncology|August 15, 2019
The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative OutcomesElio Mazzone, Felix Preisser, Sebastiano Nazzani, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|October 14, 2016
Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare databaseJonas Schiffmann, Maxine Sun, Giorgio Gandaglia, et al.
European Urology Focus|March 19, 2021
Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical NephroureterectomyClaudia Collà Ruvolo, Luigi Nocera, L Franziska Stolzenbach, et al.
Cancers|June 10, 2022
High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer PatientsKaren Geoffroy, Patrick Laplante, Sylvie Clairefond, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical CystectomyPaolo Dell'Oglio, Zhe Tian, Sami-Ramzi Leyh-Bannurah, et al.
International Journal of Cancer|May 13, 2008
Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 menAndrea Gallina, Nazareno Suardi, Francesco Montorsi, et al.
European Urology Focus|December 19, 2017
A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian IndividualsMarco Bandini, Michele Marchioni, Felix Preisser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
European Urology|May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safetyHimisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Lab on a Chip|January 24, 2019
Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumorsKayla Simeone, Robin Guay-Lord, Mohammad Abdul Lateef, et al.
Pageof 113

Showing results (431-440 of 1,126) with videos related to

Sort By:
Pageof 113
European Urology Oncology|August 15, 2019
The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative OutcomesElio Mazzone, Felix Preisser, Sebastiano Nazzani, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|October 14, 2016
Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare databaseJonas Schiffmann, Maxine Sun, Giorgio Gandaglia, et al.
European Urology Focus|March 19, 2021
Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical NephroureterectomyClaudia Collà Ruvolo, Luigi Nocera, L Franziska Stolzenbach, et al.
Cancers|June 10, 2022
High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer PatientsKaren Geoffroy, Patrick Laplante, Sylvie Clairefond, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical CystectomyPaolo Dell'Oglio, Zhe Tian, Sami-Ramzi Leyh-Bannurah, et al.
International Journal of Cancer|May 13, 2008
Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 menAndrea Gallina, Nazareno Suardi, Francesco Montorsi, et al.
European Urology Focus|December 19, 2017
A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian IndividualsMarco Bandini, Michele Marchioni, Felix Preisser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
European Urology|May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safetyHimisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Lab on a Chip|January 24, 2019
Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumorsKayla Simeone, Robin Guay-Lord, Mohammad Abdul Lateef, et al.
Pageof 113